These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 37693943)
1. Modifying immune responses to adeno-associated virus vectors by capsid engineering. Bentler M; Hardet R; Ertelt M; Rudolf D; Kaniowska D; Schneider A; Vondran FWR; Schoeder CT; Delphin M; Lucifora J; Ott M; Hacker UT; Adriouch S; Büning H Mol Ther Methods Clin Dev; 2023 Sep; 30():576-592. PubMed ID: 37693943 [No Abstract] [Full Text] [Related]
2. Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer. Rogers GL; Suzuki M; Zolotukhin I; Markusic DM; Morel LM; Lee B; Ertl HC; Herzog RW J Innate Immun; 2015; 7(3):302-14. PubMed ID: 25612611 [TBL] [Abstract][Full Text] [Related]
3. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574 [TBL] [Abstract][Full Text] [Related]
4. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion. Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965 [TBL] [Abstract][Full Text] [Related]
5. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells. Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875 [TBL] [Abstract][Full Text] [Related]
6. Complement is an essential component of the immune response to adeno-associated virus vectors. Zaiss AK; Cotter MJ; White LR; Clark SA; Wong NC; Holers VM; Bartlett JS; Muruve DA J Virol; 2008 Mar; 82(6):2727-40. PubMed ID: 18199646 [TBL] [Abstract][Full Text] [Related]
7. Improved Genome Packaging Efficiency of Adeno-associated Virus Vectors Using Rep Hybrids. Mietzsch M; Eddington C; Jose A; Hsi J; Chipman P; Henley T; Choudhry M; McKenna R; Agbandje-McKenna M J Virol; 2021 Sep; 95(19):e0077321. PubMed ID: 34287038 [TBL] [Abstract][Full Text] [Related]
8. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. Mays LE; Vandenberghe LH; Xiao R; Bell P; Nam HJ; Agbandje-McKenna M; Wilson JM J Immunol; 2009 May; 182(10):6051-60. PubMed ID: 19414756 [TBL] [Abstract][Full Text] [Related]
9. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. Zhu J; Huang X; Yang Y J Clin Invest; 2009 Aug; 119(8):2388-98. PubMed ID: 19587448 [TBL] [Abstract][Full Text] [Related]
10. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. Li C; Hirsch M; Asokan A; Zeithaml B; Ma H; Kafri T; Samulski RJ J Virol; 2007 Jul; 81(14):7540-7. PubMed ID: 17475652 [TBL] [Abstract][Full Text] [Related]
11. Structural and Biophysical Analysis of Adeno-Associated Virus Serotype 2 Capsid Assembly Variants. Bennett A; Gargas J; Kansol A; Lewis J; Hsi J; Hull J; Mietzsch M; Tartaglia L; Muzyczka N; Bhattacharya N; Chipman P; Agbandje-McKenna M; McKenna R J Virol; 2023 Jul; 97(7):e0177222. PubMed ID: 37310260 [TBL] [Abstract][Full Text] [Related]
12. AAV capsid engineering identified two novel variants with improved in vivo tropism for cardiomyocytes. Rode L; Bär C; Groß S; Rossi A; Meumann N; Viereck J; Abbas N; Xiao K; Riedel I; Gietz A; Zimmer K; Odenthal M; Büning H; Thum T Mol Ther; 2022 Dec; 30(12):3601-3618. PubMed ID: 35810332 [TBL] [Abstract][Full Text] [Related]
13. Subretinal delivery of adeno-associated virus serotype 2 results in minimal immune responses that allow repeat vector administration in immunocompetent mice. Barker SE; Broderick CA; Robbie SJ; Duran Y; Natkunarajah M; Buch P; Balaggan KS; MacLaren RE; Bainbridge JW; Smith AJ; Ali RR J Gene Med; 2009 Jun; 11(6):486-97. PubMed ID: 19340848 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy. Gehrke M; Diedrichs-Möhring M; Bogedein J; Büning H; Michalakis S; Wildner G Cells; 2022 Jun; 11(12):. PubMed ID: 35741009 [TBL] [Abstract][Full Text] [Related]
15. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Shi W; Arnold GS; Bartlett JS Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765 [TBL] [Abstract][Full Text] [Related]